-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JSbrX0gj2ChsXL9dvkLm8etKLTP1++76tJPGwa4L0CEwW6e+z7eSPvWdqkVrjqZQ 5NP0uPXf8MT6cjqpSx1nLQ== 0001193125-04-175309.txt : 20041021 0001193125-04-175309.hdr.sgml : 20041021 20041021131434 ACCESSION NUMBER: 0001193125-04-175309 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20041021 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20041021 DATE AS OF CHANGE: 20041021 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAXTER INTERNATIONAL INC CENTRAL INDEX KEY: 0000010456 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 360781620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-04448 FILM NUMBER: 041089271 BUSINESS ADDRESS: STREET 1: ONE BAXTER PKWY STREET 2: DF2-2W CITY: DEERFIELD STATE: IL ZIP: 60015 BUSINESS PHONE: 8479482000 MAIL ADDRESS: STREET 1: ONE BAXTER PARKWAY STREET 2: DF2-2W CITY: DEERFIELD STATE: IL ZIP: 60015 FORMER COMPANY: FORMER CONFORMED NAME: BAXTER TRAVENOL LABORATORIES INC DATE OF NAME CHANGE: 19880522 FORMER COMPANY: FORMER CONFORMED NAME: BAXTER LABORATORIES INC DATE OF NAME CHANGE: 19760608 8-K/A 1 d8ka.htm AMENDMENT NO. 1 TO FORM 8-K Amendment No. 1 to Form 8-K

 

   

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

    
       

 

 

 

FORM 8-K/A

Amendment No. 1

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

Date of Report (Date of earliest event reported)

October 21, 2004

 

 

Baxter International Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   1-4448   36-0781620

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

 

One Baxter Parkway, Deerfield, Illinois

   60015
(Address of principal executive offices)   (Zip Code)

 

 

Registrant’s telephone number, including area code

847.948.2000

 

 

 
(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

EXPLANATORY NOTE: This Form 8-K/A is being filed solely to correct a typographical error in the schedule to the company’s press release dated October 21, 2004 entitled “Key Product Line Sales—US/International” which is on page 13 of Exhibit 99. The corrected schedule is filed with this Form 8-K/A, and indicates that the growth rate in the U.S. for Bioscience-Other was negative 47% for the third quarter of 2004, as compared to the third quarter of 2003 (not positive 47%).

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

BAXTER INTERNATIONAL INC.
                    (Registrant)
By:  

/s/ Jan Stern Reed

    Jan Stern Reed
    Corporate Secretary

 

Date: October 21, 2004

Exhibit Index

 

Exhibit No.
  

Description

99   Corrected Schedule—Key Product Line Sales—US/International
 EX-99 2 dex99.htm CORRECTED SCHEDULE -- KEY PRODUCT LINE SALES -- US / INTERNATIONAL Corrected Schedule -- Key Product Line Sales -- US / International

BAXTER—PAGE 13

 

Baxter International Inc.

Key Product Line Sales—US/International

Period Ending September 30, 2004

(unaudited)

 

($ in millions)    Q3 2004
    Q3 2003
    % Growth
  
   US    International    Total    US    International    Total    US     International     Total  

BioScience

                                                         

Recombinants

    $ 153    $   188    $ 341    $ 154    $   137    $ 291    (1% )   38%     17%  

Plasma Proteins 1

      135    119      254      116    135      251    16%     (12% )   1%  

Antibody Therapy

      49    33      82      45    32      77    8%     4%     6%  

Transfusion Therapies

      62    62      124      63    70      133    (2% )   (11% )   (7% )

Other 2

      9    39      48      17    51      68    (47% )   (24% )   (29% )

Total BioScience

    $ 408    $   441    $ 849    $ 395    $   425    $ 820    3%     4%     4%  

Medication Delivery

                                                         

IV Therapies 3

    $ 93    $   182    $ 275    $ 106    $   169    $ 275    (12% )   8%     0%  

Drug Delivery

      136    50      186      132    43      175    3%     15%     6%  

Electronic Infusion Systems

      178    49      227      150    46      196    19%     7%     16%  

Anesthesia

      179    17      196      180    17      197    (1% )   1%     0%  

Other 4

      7    95      102      7    95      102    0%     0%     0%  

Total Medication Delivery 5

    $ 593    $   393    $ 986    $ 575    $   370    $ 945    3%     6%     4%  

Renal

                                                         

PD Therapy

    $ 65    $   296    $ 361    $ 64    $   275    $ 339    2%     8%     7%  

HD Therapy

      36    87      123      29    78      107    24%     12%     15%  

Other

      0    1      1      4    1      5    (100% )   0%     (80% )

Total Renal

    $ 101    $   384    $ 485    $ 97    $   354    $ 451    4%     8%     8%  

TOTAL BAXTER

    $ 1,102    $1,218    $ 2,320    $ 1,067    $1,149    $ 2,216    3%     6%     5%  

 

1 Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.
2 Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).
3 Principally includes intravenous solutions and nutritional products.
4 Principally includes oncology and other hospital-distributed products.
5 Sales of pain management products, which were previously included in Anesthesia, are now reported in Electronic Infusion Systems or Other, depending on the product. All prior sales data has been reclassified to reflect this change.

Note: In August 2004, the company restated its previously issued financial statements for 2001 through 2003 and the first quarter of 2004. This information reflects the restatements. Refer to the company’s Form 10-K/A for the year ended December 31, 2003 and Forms 10-Q/A for the quarters ended March 31, 2004 and September 30, 2003 for further information.

-----END PRIVACY-ENHANCED MESSAGE-----